Search - tctmd.com

Displaying 101 - 120 of 352

Sort: Relevancy | Date

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Daily News

‘Classic’ Takotsubo? Not So Fast: Different Presentations Could Spell Diverse Prognoses

Yael L. Maxwell

August 16, 2018

News Daily News

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

L.A. McKeown

August 09, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Daily News

TAVR Readmissions Similar to Surgery’s at 30 Days, but Costs Are Higher

L.A. McKeown

May 11, 2018

News Daily News

PCI Public Reporting: Where Some Point to Problems, Others Propose Solutions

Caitlin E. Cox

May 09, 2018

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Todd Neale

April 24, 2018

News Daily News

New Surgical Valve Durability Data Set ‘Critical Benchmark’ for TAVR Devices

Yael L. Maxwell

March 26, 2018

News Daily News

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

Michael O'Riordan

February 12, 2018

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

News Daily News

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

L.A. McKeown

December 11, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

Multivessel PCI Debate: Based on What We Know Today - Culprit Lesion Only PCI With Watchful Waiting Is the Preferred Strategy!

Presenter: Stefan K. James, Ran Kornowski, Deepak L. Bhatt

October 31, 2017

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

Todd Neale

August 30, 2017

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

Todd Neale

August 29, 2017

News Daily News

TAVR in the US: Regional Variations in Numbers, Outcomes

Michael O'Riordan

August 22, 2017

Advertisement

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

‘Classic’ Takotsubo? Not So Fast: Different Presentations Could Spell Diverse Prognoses

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

TAVR Readmissions Similar to Surgery’s at 30 Days, but Costs Are Higher

PCI Public Reporting: Where Some Point to Problems, Others Propose Solutions

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

New Surgical Valve Durability Data Set ‘Critical Benchmark’ for TAVR Devices

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Multivessel PCI Debate: Based on What We Know Today - Culprit Lesion Only PCI With Watchful Waiting Is the Preferred Strategy!

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

P2Y12 Inhibitor Pretreatment Questioned in STEMI

TAVR in the US: Regional Variations in Numbers, Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content